EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet

Marialuisa de Ceglia iD, Nabila Rasheed iD, Rubén Tovar, Inés Pareja-Cerbán iD, Andrea Arias-Sáez, Ana Gavito iD, Silvana Gaetani iD, Carlo Cifani iD, Fernando Rodríguez de Fonseca iD, Juan Decara iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marialuisa de Ceglia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Neuropsicofarmacología, Instituto IBIMA-Plataforma BIONAND, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Má…. Hauptthemen laut MEDLINE: Diet, High-Fat, Fructose, PPAR alpha, Receptor, Cannabinoid, CB1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejería de Salud y Familias, Junta de Andalucía, Proyecto de Investigación en Salud, ISCIII co-funded by European Social Fund, "Investing in your future", Gobierno de España, Consejería de Salud y Consumo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity remains a major epidemic in developed countries, with a limited range of effective pharmacological treatments. The pharmacological modulation of PPARα, CB1, or GLP-1 receptor activity has demonstrated beneficial effects, including anti-obesity actions. In this study, we evaluated a novel amide derivative of oleic acid and tyrosol (Oleyl hydroxytyrosol ether, OLHHA), a PPARα agonist, and CB1 antagonist, in combination with the GLP-1 agonist liraglutide (LIG), as an effective multitarget therapy to improve both the peripheral and central alterations in an animal model of diet-induced obesity. In rats, exposure to a high-fat high-fructose diet (HFHFD) induced weight gain and increased plasma triglycerides, LDL, and hepatic parameters. In the brain, the HFHFD provoked disruptions in the expression of proteins regulating food intake, the endocannabinoid system, the insulin pathway, and inflammation and resulted in altered tau expression and phosphorylation, thus indicating neurodegenerative changes. Based on our results, the administration of LIG or OLHHA alone was insufficient to completely reverse the alterations noticed at the peripheral and central levels. On the other hand, the combined treatment with both compounds (OLHHA+LIG) was the most effective in promoting body weight loss and ameliorating both the central and peripheral alterations induced by HFHFDs in rats. This multitarget therapeutic approach could represent a promising strategy for treating obesity and associated comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, High-FatFructosePPAR alphaReceptor, Cannabinoid, CB1ObesityGlucagon-Like Peptide 1AnimalsRatsMaleLiraglutideRats, WistarPhenylethyl Alcohol

Stichwörter der Autor:innen

GLP-1braindietendocannabinoid systeminsulin pathwayobesitytau phosphorylation

Substanzen

FructosePPAR alphaReceptor, Cannabinoid, CB1Glucagon-Like Peptide 1LiraglutidePhenylethyl Alcohol

Autor:innen und Institutionen

  • Grupo de Neuropsicofarmacología, Instituto IBIMA-Plataforma BIONAND, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, Av. de Carlos Haya, 29010 Málaga, Spain.
  • School of Pharmacy, Pharmacology Unit, University of Camerino, 62032 Camerino, Italy.
  • Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, 00185 Rome, Italy.

ORCID-Profile: Marialuisa de Ceglia, Nabila Rasheed, Inés Pareja-Cerbán, Ana Gavito, Silvana Gaetani, Carlo Cifani, Fernando Rodríguez de Fonseca, Juan Decara

Förderung

  • Consejería de Salud y Familias, Junta de Andalucía, Proyecto de Investigación en Salud
  • ISCIII co-funded by European Social Fund, "Investing in your future", Gobierno de España
  • Consejería de Salud y Consumo
  • ISCIII co-funded by European Social Fund, “Investing in your future”, Gobierno de España

Zitieren

APA

de Ceglia, M., Rasheed, N., Tovar, R., Pareja-Cerbán, I., Arias-Sáez, A., Gavito, A., Gaetani, S., Cifani, C., Rodríguez de Fonseca, F., & Decara, J. (2025). A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062420

Vancouver

de Ceglia M, Rasheed N, Tovar R, Pareja-Cerbán I, Arias-Sáez A, Gavito A, et al. A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062420

BibTeX
@article{deCeglia2025,
  author = {de Ceglia, Marialuisa and Rasheed, Nabila and Tovar, Rubén and Pareja-Cerbán, Inés and Arias-Sáez, Andrea and Gavito, Ana and Gaetani, Silvana and Cifani, Carlo and Rodríguez de Fonseca, Fernando and Decara, Juan},
  title = {A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062420}
}
Kostenlos starten →